Skip to main content
Cerezyme® (imiglucerase) for injection logo

Gaucher Disease Type 1 Prevalence


Gaucher disease is a rare, progressive, genetic disorder that results in multi-organ dysfunction

Over 90% of patients are type 1, which can be effectively managed once diagnosed.1,2

Gaucher disease type 1 is more prevalent than you think

More than 90% of patients with Gaucher disease have type 1.2 Although Gaucher disease type 1 is a rare genetic condition, it’s important to understand its occurrence in different patient populations.

Estimated prevalence of Gaucher disease type 13,4

~1 in 50,000 to 1 in 100,000

Panethnic and occurs in ~1 in 50,000 to 1 in 100,000 in the general population

~1 in 500 to 1 in 1,000

More common in people of Ashkenazi Jewish heritage

~90%

of Jewish Americans are of Ashkenazi Jewish heritage

  • In patients of Ashkenazi Jewish heritage, the frequency of Gaucher disease has a higher incidence (~1 in 500 to 1 in 1,000) than hematologic malignancies (~1 in 2,500)2
  • In patients of Ashkenazi Jewish heritage, ~1 in 12 is a carrier5
  • Despite the high frequency of Gaucher disease among patients of Ashkenazi Jewish heritage, Gaucher disease type 1 is panethnic2
Badge icon representing 30 years

Gaucher disease type 1 is manageable once diagnosed

When an ERT is needed, choose the longest-approved therapy

Checkmark icon

An established ERT for children ages 2 and up

Studied in the largest reported group of pediatric patients with Gaucher disease type 1

ERT=enzyme replacement therapy.

Indication

Cerezyme® (imiglucerase) for injection is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adult and pediatric patients. 

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS
Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate CEREZYME in a healthcare setting with appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue CEREZYME immediately, and initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and to seek immediate medical care should symptoms occur.

Warnings and Precautions:

Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING.
Patients with antibody to imiglucerase have a higher risk of hypersensitivity reactions. Consider periodic monitoring during the first year of treatment for IgG antibody formation.

Consider risks and benefits of readministering Cerezyme to individual patients following a severe reaction. If a mild or moderate hypersensitivity reaction occurs, consider reducing the rate of infusion, pretreat with antihistamines and/or corticosteroids, and monitor patients for new signs and symptoms of a hypersensitivity reaction. 

Infusion-Associated Reactions:
Infusion associated reactions (IARs) have been observed in patients treated with Cerezyme. If a severe IAR occurs, discontinue CEREZYME and immediately initiate appropriate medical treatment. Consider the risks and benefits of re-administering CEREZYME following a severe IAR. If a mild or moderate IAR occurs, consider decreasing the infusion rate, temporarily stopping the infusion, and/or administering antihistamines, antipyretics, and/or corticosteroids.

Adverse Reactions:

  • Adverse reactions reported in adults and pediatric patients include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting. 

Please see accompanying Full Prescribing Information, including Boxed WARNING.

Indication

Important Safety Information

References: 1. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82(8):697-701. 2. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110-115. 3. Nalysnyk L et al. Hematology. 2017;22(2):65-73. 4. National Human Genome Institute. About Gaucher disease. National Institutes of Health. Updated January 4, 2012. Accessed August 2, 2025. www.genome.gov/Genetic-Disorders/Gaucher-Disease 5. Mistry PK, Weinthal JA, Weinreb NJ. Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion. Clin Adv Hematol Oncol. 2012;10(6 Suppl 8):1-16.

© 2025 Sanofi. All rights reserved. Cerezyme and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2015574-v3.0-08/2025